Research-Varicella Vaccine Efficacy

General Information
Program/Project Name: Strengthening the Evidence Base Measuring Effectiveness of Two Doses of Varicella Vaccine

Funding Category: Serving the Most Vulnerable

Program Description
Federal Grant Name: American Recovery and Reinvestment Act (ARRA) – Section 317 Immunization Program: Strengthening the Evidence Base Measuring Effectiveness of Two Doses of Varicella Vaccine – U01

Programs Supported Through Funding: Immunization Research, Division of Disease Control, Department of Public Health

Why Apply for this Grant?
Philadelphia is one of two sentinel surveillance sites in US for determining varicella incidence and varicella vaccine efficacy. This important study could only be conducted in Philadelphia and is key to guiding future CDC recommendations on use of varicella vaccine. Results have national impact on health policy decisions.

Program Objectives: The Philadelphia Department of Public Health (PDPH) in collaboration with the Centers for Disease Control and Prevention (CDC) will conduct a matched, case-control study to examine the incremental effectiveness of the 2-dose varicella vaccination regimen compared to the 1-dose regimen in preventing breakthrough varicella disease among school-aged children in Philadelphia. Secondary study objectives are to a) determine risk factors (demographic variables, underlying conditions, recent varicella-zoster virus (VZV) exposures, and time since vaccination) associated with varicella disease among 2- dose varicella vaccine recipients and b) determine the clinical presentation of breakthrough varicella in 2-dose compared with 1-dose varicella vaccine recipients.

Grant Achievements for the Quarter: During this quarter, the Philadelphia Department of Public Health (PDPH) continued work on a case-control evaluation of the incremental effectiveness of the 2-dose varicella vaccine regimen compared to the 1-dose regimen in preventing breakthrough varicella (chickenpox) disease among children in Philadelphia. Between July 2011 and September 2011, staff completed study enrollment and recruited 10 new varicella case subjects and 63 control subjects (final overall number of participants: 64 cases and 227 control subjects).  During this quarter, project staff also submitted monthly progress reports to the CDC and participated in conference calls with CDC and the California VASP site to discuss study activities.

Actual # of FTE jobs created for the quarter*:

Q8: 1.01

Q9: 1.01

Q10: 0

*In the City of Philadelphia’s quarterly federal report, also know as Section 1512 reports, jobs are calculated based on hours worked, instead of the number of people at work. It also looks only at jobs funded directly by the Recovery Act, and does not include jobs created indirectly. Direct jobs are counted quarterly and are not cumulative.

Advertisements
This entry was posted in Research, Serving the Most Vulnerable, Varicella Vaccine Efficacy. Bookmark the permalink.